ArticleHuman mutation2026
YIF1B Mutational Dysregulation Drives Cutaneous Melanoma Progression by Remodeling the TME.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- YIF1B Mutational Dysregulation Drives Cutaneous Melanoma Progression by Remodeling the TME.Human mutation · 2026Article
- Cancer immunoediting in the melanoma tumor microenvironment: from immune elimination to therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
YIF1B, a transmembrane protein involved in intracellular trafficking and signaling, is dysregulated in multiple cancers, but its role in SKCM remains unclear. We integrated multiomics data from cutaneous melanoma cohorts, including gene expression, DNA methylation, and somatic mutation profiles. Using the similarity network fusion (SNF) algorithm, we performed molecular subtyping based on prognosis-associated epigenetic and mutational features. Finally, the biological role of YIF1B was validated in A-375 and A-875 melanoma cell lines using qRT-PCR, wound healing, and transwell migration/invasion assays following shRNA-mediated knockdown. Patients assigned to the worst-prognosis CS5 subtype exhibited poorer survival (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.